Yeon Hee Park

机构：Samsung (South Korea), Samsung Medical Center, The Catholic University of Korea Daejeon St. Mary's Hospital, St. Mary's Hospital, Sungkyunkwan University · ORCID：0000-0003-4156-9212

发表论文 416 篇 · 总被引 18009 次 · h-index 49

代表论文

Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial (2025 · Annals of Oncology · 被引 4)
Supplementary Figure S4 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer (2026)
Supplementary Table S7 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer (2026)
Table 2 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer (2026)
Table 1 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer (2026)
Data from Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial (2026)